Literature DB >> 1981528

Pharmacokinetics, N1-glucuronidation, and N4-acetylation of sulfa-6-monomethoxine in humans.

T B Vree1, E W Beneken Kolmer, Y A Hekster, M Shimoda, M Ono, T Miura.   

Abstract

Sulfamonomethoxine (S) is metabolized by O-dealkylation, N4-acetylation, and N1-glucuronidation. In humans, only N1-glucuronidation (12%) and N4-acetylation (36%) takes place. The N1-glucuronide is directly measured by HPLC. When N4-acetylsulfamonomethoxine (N4) is administered as the parent drug, N1-glucuronidation does not occur. After an oral dose, fast and slow acetylators show a similar t1/2 for S (25.0 +/- 4.6 hr vs. 29.8 +/- 4.8 hr; p = 0.459), and the t1/2 of the N4-acetyl conjugate is also similar in fast and slow acetylators (25.0 +/- 4.64 hr vs. 29.8 +/- 4.8 hr, p = 0.459). The intrinsic mean residence time of N4 is 7.1 +/- 2.3 hr. The mean total body clearance of S is 5.0 +/- 1.3 ml/min, the renal clearance is 0.84 +/- 0.26 ml/min, and the volume of distribution at steady state is 11.7 +/- 3.4 liters. The renal clearance of N4 is 17.89 +/- 4.19 ml/min. No measurable concentrations of the N1-glucuronide of S are found in plasma. The protein binding of S is 92%. N1-glucuronidation results in an 80% reduction in the protein binding of S (11%). N4 shows a high protein binding of 98%. Approximately 60% of the oral dose of S is excreted in the urine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981528

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

1.  High pressure liquid chromatographic analysis and preliminary pharmacokinetics of sulfaphenazole and its N2-glucuronide and N4-acetyl metabolites in plasma and urine of man.

Authors:  T B Vree; E W Beneken Kolmer; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

Review 2.  Drug interactions at the renal level. Implications for drug development.

Authors:  P L Bonate; K Reith; S Weir
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

3.  Direct measurement of probenecid and its glucuronide conjugate by means of high pressure liquid chromatography in plasma and urine of humans.

Authors:  T B Vree; E W Beneken Kolmer
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

4.  Probenecid inhibits the renal clearance and renal glucuronidation of nalidixic acid. A pilot experiment.

Authors:  T B Vree; M Van den Biggelaar-Martea; E W Van Ewijk-Beneken Kolmer; Y A Hekster
Journal:  Pharm World Sci       Date:  1993-08-20

5.  Direct gradient reversed-phase HPLC analysis and preliminary pharmacokinetics of nalidixic acid, 7-hydroxymethylnalidixic acid, 7-carboxynalidixic acid, and their corresponding glucuronide conjugates in humans.

Authors:  T B Vree; M van den Biggelaar-Martea; E W van Ewijk-Beneken Kolmer; Y A Hekster
Journal:  Pharm World Sci       Date:  1993-06-18

6.  Direct high pressure liquid chromatographic analysis and preliminary pharmacokinetics of enantiomers of oxazepam and temazepam with their corresponding glucuronide conjugates.

Authors:  T B Vree; A M Baars; E W Wuis
Journal:  Pharm Weekbl Sci       Date:  1991-04-26

7.  Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study.

Authors:  T B Vree; E W Van Ewijk-Beneken Kolmer; E W Wuis; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1992-10-16

8.  Pharmacokinetics, N1-glucuronidation and N4-acetylation of sulfamethomidine in humans.

Authors:  T B Vree; E W Beneken Kolmer; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1991-10-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.